Skip to main content

Advertisement

SpringerLink
Log in

PARKINSON DISEASE

Pathogenetic insights into young-onset Parkinson disease

  • News & Views
  • Published:

From Nature Reviews Neurology

View current issue Sign up to alerts

An understanding of the biochemical processes underlying Parkinson disease (PD) will be essential for the development of disease-modifying therapies. In a recent study, a novel biochemical phenotype of the disease was identified from analysis of inducible pluripotent stem cell-derived dopaminergic neurons from individuals with young-onset PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Marras, C. et al. Prevalence of Parkinson’s disease across North America. NPJ Parkinsons Dis. 4, 21 (2018).

    Article  CAS  Google Scholar 

  2. Toulorge, D., Schapira, A. H. V. & Hajj, R. Molecular changes in the postmortem parkinsonian brain. J. Neurochem. 139, 27–58 (2016).

    Article  CAS  Google Scholar 

  3. Kilarski, L. L. et al. Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson’s disease. Mov. Disord. 27, 1522–1529 (2012).

    Article  CAS  Google Scholar 

  4. Nalls, M. A. et al. Genetic risk and age in Parkinson’s disease: continuum not stratum. Mov. Disord. 30, 850–854 (2015).

    Article  CAS  Google Scholar 

  5. Malek, N. et al. Features of GBA-associated Parkinson’s disease at presentation in the UK Tracking Parkinson’s study. J. Neurol. Neurosurg. Psychiatry 89, 702–709 (2018).

    Article  Google Scholar 

  6. Laperle, A. H. et al. iPSC modeling of young-onset Parkinson’s disease reveals a molecular signature of disease and novel therapeutic candidates. Nat. Med. 26, 289–299 (2020).

    Article  CAS  Google Scholar 

  7. Burbulla, L. F. et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease. Science 357, 1255–1261 (2017).

    Article  CAS  Google Scholar 

  8. Robak, L. A. et al. Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease. Brain 140, 3191–3203 (2017).

    Article  Google Scholar 

  9. Balestrino, R. & Schapira, A. H. V. Glucocerebrosidase and Parkinson disease: molecular, clinical, and therapeutic implications. Neuroscientist 24, 540–559 (2018).

    Article  CAS  Google Scholar 

  10. Mullin, S. et al. Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2019.4611 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, UK

    Anthony H. V. Schapira & Huw R. Morris

Authors
  1. Anthony H. V. Schapira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huw R. Morris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony H. V. Schapira.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schapira, A.H.V., Morris, H.R. Pathogenetic insights into young-onset Parkinson disease. Nat Rev Neurol 16, 245–246 (2020). https://doi.org/10.1038/s41582-020-0343-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-020-0343-5

  • Springer Nature Limited

This article is cited by

Search

Navigation